leisure time -WSS

leisure time

author：focus 2025-09-03 18:40:38 - browse：833

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Warren pushes Witty on UnitedHealth's control over physicians

hotspot

WSS

Emergency workers more likely to restrain Black patients: study

FDA panel to weigh approval of NurOwn, controversial ALS drug

As billionaires fund anti

Why are Kaiser Permanente staff considering a strike?

Biotech stock slump in 2023: awaiting the turnaround

Experts study whether long Covid risk adds up with each reinfection

explore

leisure time

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

FDA panel to weigh approval of NurOwn, controversial ALS drug

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Hepatitis C has a cure — but many Americans still lack access to it

As health system earnings go up, health insurance stocks go down

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Medical student insurance fails on mental health care coverage

Novavax promises a turnaround & Lilly roils the obesity market

It's been 20 years since Dolly the sheep. Where's my clone?

Wikipedia

The effects of a landmark ruling on DNA ownership are becoming clearer

Brain technologies pose threats that are all too real, experts warn

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

FDA panel to weigh approval of NurOwn, controversial ALS drug

Ukraine and a new approach to mental health in war

hotspot

hotspot

focus

focus